Alzinova AB, Stockholm, Sweden, have announced its upcoming clinical study for Alzheimer’s disease vaccine candidate ALZ-101, which will take place in the second quarter of 2021.
The subjects of this phase 1 study will be early Alzheimer’s disease patients. This is the first in human study of the ALZ-101 vaccine, its primary objective is to assess the tolerability or adverse effects. The study will also analyse the immune response, and will be conducted in Finland in cooperation with the Clinical Research Services Turku.
Alzinova AB is a biotherapy company focused on an immunotherapy approach to Alzheimer’s disease.
Kristina Torfgård, CEO of Alzinova AB, commented, “On the basis of the documented pre-clinical properties of the ALZ-101 vaccine candidate, we are truly looking forward to the clinical development of ALZ-101 into a therapeutic vaccine for patients. To the best of our knowledge, this is the first clinical study that specifically targets the toxic forms of the Aβ peptide, and it will thus be the first of its kind. This is an important step for Alzinova, in a field where the medical need is great.”
